Allysta Pharmaceuticals develops first-in-class therapeutic peptides targeting adiponectin signaling pathways to address muscle degeneration in Duchenne muscular dystrophy (DMD). Their lead drug, ALY688ER, has demonstrated the ability to reduce muscle cell death and enhance muscle regeneration in preclinical models, offering potential benefits for other inflammatory and fibrotic conditions.

Elucida Oncology develops targeted CDot Drug Conjugates (CDCs) to deliver precise therapeutic agents directly to primary solid tumors and metastatic cancer cells. This approach enhances treatment efficacy while minimizing damage to surrounding healthy tissue, addressing the need for more effective cancer therapies.

HARM provides an AI-powered platform for individuals experiencing harm to quickly access immediate, trusted support. The system intelligently identifies the nature of the reported harm and routes users directly to appropriate, city-approved advocacy, legal, or housing resources. This streamlined process eliminates confusion while generating de-identified data insights to help municipal leaders optimize community support services.

Provides a shared progress tracking platform for coaches and clients, enabling clients to log actions, track goals, and maintain accountability between sessions. Coaches gain measurable insights into client progress and engagement through customizable logs, reminders, and real-time feedback tools, improving the effectiveness of their practice.

MyZenTeam provides an employee engagement platform that consolidates team data into a secure database, enabling real-time access and management from any device. The app enhances team connectivity and recognition by facilitating personalized celebrations and insights, addressing the challenges of engagement in hybrid and remote work environments.

This company develops therapeutics designed to enhance and protect microglia, the immune cells of the brain. Their approach utilizes generative AI and biomarker technology to address the declining debris clearance function associated with aging and neurological disease. The core value is improving brain health by restoring microglial function to clear harmful pathogens and cellular debris.

The startup develops topical therapeutic drugs targeting inflammatory ophthalmic diseases, utilizing specialized formulations to enhance drug delivery to affected tissues. This approach addresses the need for effective treatments for patients suffering from conditions that currently lack adequate therapeutic options.

Science is a clinical-stage technology company developing biohybrid neural interfaces and advanced neural recording electronics to address serious unmet medical needs in neuroscience. Their technologies aim to enhance neural communication and restore vision, facilitating new treatment possibilities for patients with neurological disorders.

ForwardVue Pharma develops novel therapeutics to reduce the treatment burden for patients with retinal diseases. The company is focused on a patent-protected, long-acting ORAI1 blocker administered via intravitreal injection for up to 12 months. This platform targets retinal neovascular disease by acting both upstream and downstream of existing VEGF inhibition treatments.